Faes Farma Plans to Grow by Double Digits in Latin America

Faes Farma explains its future plans after eleven consecutive years of growing turnover. The Spanish pharmaceutical company predicts a double-digit increase in Latin America and the expansion of its medical visit and animal nutrition and health businesses. It also anticipates a reinforcement of its commitment to research, development and innovation (R&D&I) with the opening of a new industrial plant in Derio, Basque Country, and closing in 2024, growing between 6% and 8%. in revenue and between 3% and 5% in its gross operating result (ebitda).

The pharmaceutical group celebrated its Capital Markets Day, in which it assessed the milestones achieved last year and the strategic lines for the future. In this context, Faes Farma has detailed that the Derio plant will begin operating at the end of 2024, once the mandatory inspections are carried out and permits are issued from the regulators involved. Once the licenses are granted, the company will move the production lines to the new factory, concluding this process in 2026 .

With this new investment, Faes Farma intends to strengthen its third-party manufacturing business until it doubles its production capacities compared to its other factory in Leioa.

If you want to find more details about Faes Farma and to find the most important financial news of the day, download for free our companion app Born2Invest.

Faes Farma will invest 23 million euros in a factory focused on animal food and health

The Spanish pharmaceutical company also plans to open a new plant focused on the nutrition and animal health business in Huesca, intended to produce feed for the pig sector. This new manufacturing center has an investment of 23 million euros and is expected to produce around 120,000 tons of food per year .

With this there will be eight company plants around the world: four dedicated to the pharmaceutical sector, in Derio, Leioa, Portugal and Guatemala, and four more to the production of food and drugs for animals, two in Huesca, one in Tarragona and another in Lanziego.

Faes Farma is also committed to R&D&I developing solutions in the areas of allergies, gastrointestinal, bone immunomodulation and pain, which have a potential market of around 23 billion euros. To this end, the pharmaceutical company has six ongoing projects for which it will begin clinical trials in 2025 plus 21 active projects after several launches in 2023.

__

(Featured image by Marek Studzinski via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the articles from the originals. In case of discrepancy, the originals will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us